Comparative Pharmacology
Head-to-head clinical analysis: AURYXIA versus SEVELAMER CARBONATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AURYXIA versus SEVELAMER CARBONATE.
AURYXIA vs SEVELAMER CARBONATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AURYXIA (ferric citrate) is a phosphate binder that reduces serum phosphate by binding dietary phosphate in the gastrointestinal tract, forming insoluble ferric phosphate complexes that are excreted in the feces. The iron component also increases serum iron parameters and may improve iron stores.
Sevelamer carbonate is a phosphate-binding polymer that binds dietary phosphate in the gastrointestinal tract, thereby reducing phosphate absorption and serum phosphate levels. It also binds bile acids and may reduce LDL cholesterol.
Adult: 1 tablet (1700 mg ferric citrate) three times daily with meals, titrated every 2-4 weeks to achieve target serum phosphate levels. Maximum dose: 12 tablets per day.
Adults: 800 to 1600 mg orally three times daily with meals, titrated according to serum phosphorus targets.
None Documented
None Documented
Not applicable; systemic absorption is minimal. AURYXIA is not absorbed and acts locally in the GI tract.
Not applicable. Sevelamer carbonate is not systemically absorbed and thus has no measurable plasma half-life. Its pharmacological effect correlates with gastrointestinal transit time, which is typically 24-48 hours.
Primarily fecal as unabsorbed drug (≥99%). Renal excretion is negligible (<1%).
Sevelamer carbonate is not absorbed systemically; it acts locally in the gastrointestinal tract. Excretion is entirely fecal, with no renal or biliary elimination. The polymer is excreted unchanged in the feces.
Category C
Category A/B
Phosphate Binder
Phosphate Binder